Company profile for Adiso Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Adiso holds an inspiring vision to pursue bold and novel approaches to treating inflammation and the havoc it causes on the human body. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) bo...
Adiso holds an inspiring vision to pursue bold and novel approaches to treating inflammation and the havoc it causes on the human body. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
530 Virginia Road, Suite 300, Concord, MA 01742
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-data-publication-of-two-phase-1-studies-of-first-in-class-neutrophil-modulator-ads051-in-the-american-journal-of-gastroenterology-302393958.html

PR NEWSWIRE
06 Mar 2025

https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-positive-topline-data-from-phase-1b-study-of-ads051-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-301963581.html

PR NEWSWIRE
22 Oct 2023

https://www.prnewswire.com/news-releases/adiso-therapeutics-expands-board-of-directors-with-appointment-of-robert-lisicki-301953998.html

PR NEWSWIRE
12 Oct 2023

https://www.prnewswire.com/news-releases/adiso-therapeutics-to-participate-in-upcoming-september-investor-conferences-301920146.html

PR NEWSWIRE
07 Sep 2023

https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-publication-of-compelling-preclinical-research-on-ads051-a-first-in-class-oral-gut-restricted-small-molecule-modulator-of-neutrophil-trafficking-and-activation-301876623.html

PR NEWSWIRE
13 Jul 2023

https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-publication-in-journal-of-clinical--translational-immunology-highlighting-the-ads032-mechanism-of-action-301870347.html

PR NEWSWIRE
06 Jul 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty